Upadacitinib tablets bulk supplier for pharma manufacturers

Upadacitinib Tablets 15 mg, 30 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 15 mg, 30 mg

Reference Brands: Rinvoq(US & EU)

Category: Arthritis

Upadacitinib inhibits Janus kinase (JAK) enzymes, blocking cytokine signaling involved in inflammation. It effectively reduces symptoms and disease progression in rheumatoid arthritis. Benefits include rapid relief, improved joint function, and better quality of life, with convenient oral dosing and a safety profile suitable for long-term autoimmune therapy when monitored properly.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Upadacitinib Tablets? List it or send an offer →

Product Description: Upadacitinib tablets are approved in the EU and US for moderate to severe rheumatoid arthritis. In the EU, AbbVie’s Rinvoq is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality manufacturing. In the US, FDA approval is based on extensive clinical trial data, biosimilarity, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for upadacitinib tablets, ensuring adherence to European and American standards for safe, effective autoimmune disease management, helping you navigate complex regulatory processes seamlessly.

Upadacitinib Tablets — third party manufacturing & bulk supply

Upadacitinib Tablets 15 mg, 30 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Upadacitinib Tablets is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Upadacitinib Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Upadacitinib Tablets →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Upadacitinib tablets is listed as Tablets in 15 mg, 30 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Upadacitinib tablets is referenced against Rinvoq(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.